Portfolio

BreatheAmerica, Inc

Develops and manages freestanding outpatient clinics focused on the diagnosis, treatment, and management of chronic airway diseases.


Expanding national footprint of clinics for the treatment of chronic airway diseases and infusion therapy

BreatheAmerica is a leading operator of freestanding clinics for the treatment of chronic airway diseases and infusion therapy. Headquartered in Nashville, the Company has operations in several states across the southern U.S.  The BreatheAmerica model was developed in conjunction with a leading academic hospital and offers an innovative approach to accurately diagnosing and treating some of the most prevalent respiratory and allergic conditions – sinusitis, asthma, environmental, drug, food and skin allergies, COPD, headache, cough, and others.  As a natural extension of its treatment of airway diseases, BreatheAmerica has also built a rapidly growing infusion business through its acquisition of Precision Healthcare in 2011.

Essex Woodlands acquired a minority stake in BreatheAmerica in 2011 and is actively working with BreatheAmerica’s founders and management team to grow the clinics and pursue mutually beneficial joint ventures with hospital partners.  In delivering all the necessary multi-specialty resources under one roof, BreatheAmerica’s model exemplifies the paradigm shift of “quality over quantity” occurring in the U.S. under the Affordable Care Act by demonstrating the ability to improve patient outcomes and lower costs. The Company achieves this through optimizing the treatment and medical resources needed by traditionally costly and inefficiently managed patients with chronic airway diseases.

 

 

 

 

 

 

 

 

Related News

  • BreatheAmerica Secures Series B Financing Totaling $22M
  • ““Essex Woodlands has been an exceptional partner. They understand how to nurture young companies and work with management teams. They have gone well beyond what they said they would do- an uncommon thing.” ”

    Joseph Hutts

    Chairman of the Board